GlassScriptPhysician profile
Nancy I Day
NPI 1255761185
$1,874.72
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $627 · 2022: $707 · 2023: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $622.68 | 2021-2023 | Fasenra |
| Abbvie INC. | $294.02 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $165.41 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $126.24 | 2022-2023 | Spravato |
| Amgen INC. | $100.21 | 2021-2022 | |
| Boston Scientific Corporation | $67.56 | 2023 | Watchman Flx |
| Abbott Laboratories | $65.47 | 2022 | |
| Gilead Sciences, INC. | $64.68 | 2021-2023 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.64 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.97 | 2021-2022 | |
| Mylan Specialty L.P. | $47.98 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $28.61 | 2021 | |
| Optinose US, INC. | $23.23 | 2021 | |
| Astellas Pharma US INC | $20.39 | 2023 | Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $19.32 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.93 | 2023 | |
| Grifols USA, LLC | $17.75 | 2022 | |
| Cequr Corporation | $16.25 | 2023 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $14.98 | 2022 | |
| Vanda Pharmaceuticals INC. | $14.89 | 2023 | Hetlioz |
| Glaxosmithkline, LLC. | $14.52 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Eisai INC. | $14.41 | 2022 | |
| Lilly USA, LLC | $13.58 | 2023 | Mounjaro, Trulicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.